

To Whom It May Concern

Company Name: Sawai Group Holdings Co., Ltd.

Representative: Mitsuo Sawai

President and Representative Director

(Securities Code: 4887 Prime Market of Tokyo Stock

Exchange)

Contact: Yasushi Kora

Deputy General Manager Group Finance Department

(Telephone Number: +81-6-6105-5823)

Notice Regarding Court Ruling Lawsuit Filed Against the Company's Consolidated Subsidiary

Sawai Group Holdings Co., Ltd. (hereinafter the "Company") hereby announces that on May 27, 2025, the Intellectual Property High Court of Japan (hereinafter the "IP High Court") rendered its judgment in the appellate proceedings of a patent infringement lawsuit related to Nalfurafine Hydrochloride OD Tablets 2.5µg "SAWAI" (hereinafter "Nalfurafine"), a product manufactured and marketed by Sawai Pharmaceutical Co., Ltd. (hereinafter "Sawai Pharmaceutical"), a consolidated subsidiary of the Company, as outlined below.

1. Outline

In the patent infringement lawsuit concerning the use patent of Nalfurafine, Sawai Pharmaceutical was granted a favorable judgment by the Tokyo District Court on March 30, 2021, recognizing its claim of non-infringement. However, the case was subsequently appealed to the IP High Court, which has now ruled against the Company's claim.

2. Amount of damages owed 14,290,939,291 yen

3. Impact on the Financials

The Company is currently evaluating the financial impact of the judgment and plan to amend corrections to the "Consolidated Financial Results for the Fiscal Year Ended March 31, 2025(Under IFRS)" announced on May 14, 2025. The Company will announce the impact as soon as it is confirmed.

4. Feature actions

The Company believes that the judgment rendered by IP High Court is totally unacceptable which extremely disregards the Sawai Pharmaceutical's claims in the lawsuit. The Company and Sawai Pharmaceutical will promptly take all possible legal actions, including but not limited to, a final appeal to the Supreme Court of Japan after reviewing the judgment carefully.